Xigduo XR 10/1000mg Tab: Lựa chọn hàng đầu tại Puchong, Selangor, Kuala Lumpur (KL), Malaysia Complete Wellness

Mô tả

Manufacturer
AstraZeneca Pharmaceuticals

Registraction Number
MAL20091652AZ

Active Ingredients:
- Dapagliflozin propanediol monohydrate: 10 mg
- Metformin hydrochloride (extended-release): 1000 mg
Formulation: Extended-release tablet

Xigduo XR 10/1000mg Tablet is indicated as an adjunct to diet and exercise for improving glycemic control in:

Adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Dapagliflozin component:
- Reduces the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
- Reduces the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.
Metformin component:
- Improves glycemic control in patients with type 2 diabetes mellitus.

Dosage:
- Adults and pediatric patients aged 10 years and older:
  - Dapagliflozin: Starting dose of 5 mg once daily, may increase to 10 mg once daily.
  - Metformin extended-release: Starting dose of 500 mg once daily, may increase to 2000 mg once daily.
- Maximum daily dose: Dapagliflozin 10 mg and Metformin extended-release 2000 mg.
Administration:
- Take once daily with food to reduce gastrointestinal side effects.
- Swallow the tablet whole; do not crush, chew, or split.
Renal Function Monitoring:
- Assess renal function prior to initiating treatment and periodically thereafter.
- Not recommended for use in patients with eGFR persistently below 45 mL/min/1.73 m².
Temporary Discontinuation:
- Discontinue prior to iodinated contrast imaging procedures in patients with eGFR below 60 mL/min/1.73 m².
- Withhold for at least 3 days prior to surgery or procedures associated with prolonged fasting.